share_log

Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $20

Benzinga Real-time News ·  Aug 10, 2022 10:04

Morgan Stanley analyst Michael Ulz maintains Xilio Therapeutics (NASDAQ:XLO) with a Overweight and lowers the price target from $32 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment